Medline’s industry leading track record of supplying high quality products and services to the VA system and other health care providers combined with Liventa’s innovative living donor processing technology is a truly synergistic combination.
Philadelphia, Pa. (PRWEB) February 12, 2014
Liventa Bioscience (formerly AFCell Medical), the trusted innovator in living donor birth tissues to advance wound care healing, has joined forces with industry leader Medline Industries, Inc. to enter the U.S. wound care market.
The partnership will introduce Liventa’s advanced placental-based technology to Medline’s extensive customer base of Veteran’s Administration (VA) hospitals, non-VA hospitals, home health care, wound care centers and other care providers. The partnership will allow Liventa’s innovative wound care technology to be used in the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other hard-to-heal chronic skin ulcers.
“Medline’s industry leading track record of supplying high quality products and services to the VA system and other health care providers combined with Liventa’s innovative living donor processing technology is a truly synergistic combination,” said David Buche, chief operating officer for Liventa Bioscience. “Medline’s commitment to advanced biologics for wound care combined with their supply chain management expertise creates the ideal solution for wound care centers that seek to control costs while simultaneously enhancing their quality of care.”
Medline’s extensive on-staff clinical and product expertise and exceptional sales and service organization provides a strong platform for introducing Liventa’s advanced innovation into the entire continuum of care, including hospitals, nursing homes, home health care providers and wound care centers over the course of the partnership.
As the nation's largest privately held manufacturer and distributor of health care products, Medline is a leading provider of innovative advanced wound care products, programs and educational support. Medline’s team of clinical consultants and product experts provide comprehensive wound care solutions to healthcare providers throughout the country. Overall, Medline manufactures and distributes more than 350,000 products to hospitals, extended care facilities, surgery centers, physician offices, home care agencies and providers, and retailers. Named one of the country’s "Best and Brightest Companies to Work For,” Medline is headquartered in Mundelein, Ill. and has more than 1,100 dedicated sales representatives to support its broad product line and cost management services. For more information on Medline, go to http://www.medline.com. Click here to find out how to connect with Medline on a variety of social media channels for the most recent news on initiatives, innovations and products.
About Liventa Bioscience
Liventa Bioscience is a privately held, commercial stage biotechnology company focused on bringing advanced biologics to market. Its innovative allograft tissue forms come from living donors and are available through independent distribution. Liventa is currently offering or is in the process of developing a number of advanced orthopedic biologics. These products include human collagen membrane sheets derived from placental tissues, flowable wound coverings, synovial fluid transplants and innovative new soft tissue repair implants.
Liventa’s advanced biologics for wound care include a range of placental derived coverings, which promise to significantly improve the cost/efficacy dynamic for chronic wound care patients. In addition to its strategic alliance with Medline, Liventa is also a key strategic partner with Cryoport, Inc. and Crosslink Orthopaedics.
For more information on Liventa, visit http://www.liventabioscience.com.
About Robin Young
Liventa Chief Executive Officer, Robin Young has more than three decades of experience in medical technology and is one of the leading regenerative medicine technology experts in the United States. He is the founder and CEO of the annual New York Stem Cell Summit now in its eighth year. Young is also publisher of Orthopedics This Week, a leading industry journal. He has published more than 1,000 research reports and six books regarding regenerative medicine technologies and markets. Young was named “Best on the Street” by the Wall Street Journal and was identified as one of the top ten analysts in the United States by Institutional Investor Magazine.